Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$76.9 million.

  • Intellia Therapeutics' Free Cash Flow rose 1066.93% to -$76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$412.6 million, marking a year-over-year decrease of 1365.46%. This contributed to the annual value of -$354.7 million for FY2024, which is 1308.91% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Free Cash Flow of -$76.9 million as of Q3 2025, which was up 1066.93% from -$99.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Free Cash Flow ranged from a high of -$54.8 million in Q1 2021 and a low of -$149.7 million during Q1 2025
  • Moreover, its 5-year median value for Free Cash Flow was -$86.2 million (2024), whereas its average is -$88.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 19918.06% in 2021, then surged by 3743.87% in 2024.
  • Intellia Therapeutics' Free Cash Flow (Quarter) stood at -$57.5 million in 2021, then plummeted by 63.04% to -$93.8 million in 2022, then dropped by 0.85% to -$94.6 million in 2023, then increased by 8.88% to -$86.2 million in 2024, then grew by 10.73% to -$76.9 million in 2025.
  • Its last three reported values are -$76.9 million in Q3 2025, -$99.9 million for Q2 2025, and -$149.7 million during Q1 2025.